PHAT:NASDAQ, Phathom Pharmaceuticals, Inc.

PHAT stock overview

Phathom Pharmaceuticals, Inc. (PHAT:NASDAQ) closed at $4.66 on November 20, 2026, down 8.27% on the day. The stock trades 74.5% below its 52-week high of $18.31 and 1.0% above its 52-week low of $4.62. Over the past year, it lost 68.9%. Phathom Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price
$4.66
Day change
-8.27%
Volume
1,330,427
Average volume
1,445,318
Market cap
378M+
52-week range
$4.62 – $18.31
50-day average
$6.69
200-day average
$9.86

Price action over the past year

In 252 trading sessions since November 20, 2025, PHAT closed higher on 123 days (49%). Its best day was November 11, 2026 (+15.34%) and its worst was July 30, 2026 (-22.42%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

PHAT news

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprise of vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Similar stocks

Find more stocks like PHAT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.